Setting Up the Seahorse Glycolysis Stress Test
What the Test Measures
The glycolysis stress test injects glucose, then oligomycin, then 2-deoxyglucose, and reports extracellular acidification rate (ECAR) after each step. The three derived parameters are:
| Parameter | Derived from | What it reports |
|---|---|---|
| Glycolysis | ECAR after glucose, minus non-glycolytic acidification | Acidification attributable to glucose metabolism |
| Glycolytic capacity | ECAR after oligomycin | Maximum acidification when mitochondrial ATP production is blocked |
| Glycolytic reserve | Capacity minus glycolysis | The difference, not a physiological reserve |
Important distinction. "Glycolytic reserve" is an arithmetic difference between two assay conditions. It does not mean the cell holds a store of glycolytic capacity that can be called upon in physiology; it means that forcing ATP production through glycolysis raises acidification by that amount. Papers that describe a small reserve as "metabolic inflexibility" are making an interpretive leap.
Readout note. ECAR is extracellular acidification, not glycolysis. Respiratory CO₂ contributes, and in bicarbonate-containing medium the buffering chemistry dominates. The assay is run in a bicarbonate-free, HEPES-buffered medium precisely to reduce that contribution, which also means the cells are outside their normal buffering environment for the duration.
Part 1 — Before the Run
| Parameter | Practical starting point | Why it matters |
|---|---|---|
| Seeding density | Titrate per cell type; aim for a confluent monolayer at assay time | Too sparse: signal near noise. Too dense: local hypoxia and nonlinearity |
| Attachment time | 4–24 h, consistent between plates | Attachment stress changes baseline acidification |
| Assay medium | Bicarbonate-free base, HEPES 10–25 mM, glucose-free for the test, glutamine as specified | Substrate content defines the baseline |
| Equilibration | 45–60 min at 37 °C without CO₂ | Removes bicarbonate; stabilises pH |
| Final volume | Per the plate format; usually 180–200 µL | Volume affects both diffusion and injected concentration |
| Sensor calibration | Per instrument instructions, same day | Drift masquerades as biology |
The first row is the one most often copied from another lab. Density optima differ by several fold between lines, and the correct density is the one that gives a linear relationship between cell number and ECAR in a pilot.
Part 2 — Injection Concentrations
| Injection | Typical final concentration | Note |
|---|---|---|
| Glucose | 10 mM | Saturating for most lines; check that it is saturating in yours |
| Oligomycin | 1 µM | Titrate if the response is small; incomplete ATP synthase blockade inflates capacity |
| 2-DG | 50 mM | Competitive hexokinase inhibition; also affects glycosylation |
Caveat on oligomycin. The concentration is chosen to block ATP synthase completely. In cells with high respiratory capacity or high membrane potential, 1 µM may be insufficient, and the resulting "capacity" is an underestimate. A titration in a pilot plate costs three wells and converts the assumption into a measurement.
Caveat on 2-DG. At 50 mM, 2-DG inhibits hexokinase and also interferes with glycosylation, which can induce an ER stress response within the assay window. The post-2-DG ECAR is therefore a lower bound on glycolytic acidification rather than a clean zero.
Part 3 — Cycle Settings
| Setting | Typical | Effect |
|---|---|---|
| Mix | 3 min | Equilibrates the well |
| Wait | 2–3 min | Allows the sensor to stabilise |
| Measure | 3 min | Averaged to give the rate |
| Replicates per condition | 3–5 wells minimum | Well-to-well variance dominates small effects |
| Baseline cycles before injection | 3 | Establishes stability; unstable baselines are a red flag |
Readout note. Three baseline cycles before the first injection are diagnostic, not ceremonial. If the three baseline rates differ by more than about 10%, the run should be inspected before interpretation — the cause is usually temperature, bubbles, or incomplete equilibration, and each has a different fix.
Part 4 — Normalisation
| Basis | Strength | Limitation |
|---|---|---|
| Cell count at end of assay | Direct | Requires counting per well; detachment losses |
| Total protein | Convenient | Protein content changes with treatment |
| DNA | Less treatment-sensitive than protein | Requires a reliable assay at low amounts |
| Pre-assay confluence imaging | Non-destructive | Indirect |
Normalise to a basis that the treatment does not change. If a drug reduces protein content per cell, protein normalisation will overstate the per-cell effect; if it changes cell number, well-based normalisation is essential.
Part 5 — Common Configuration Errors
- • Glucose present in the assay medium, which removes the glucose-injection response entirely.
- • Serum left in the assay medium, which adds substrates and buffering capacity.
- • Equilibration in CO₂, which leaves bicarbonate in the medium.
- • Injection volume too large, which dilutes the well and changes the cell environment.
- • Edge wells used without a layout correction, where evaporation raises effective concentrations.
- • Compound precipitation in the assay medium, which is common for poorly soluble inhibitors.
Part 6 — Where This Article Connects
The instrument-level companion to the pillar's measurement discussion; the baseline troubleshooting article covers runs that fail to stabilise, and the 2-DG article covers the inhibitor choice in more detail. Interpretation limits — what ECAR can and cannot support — are set out in the pillar and in the glycolytic enzyme article.
If you need glycolysis stress tests with density and oligomycin titration validated for your line, we can scope the work with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Optimal density, injection concentrations and cycle settings vary by cell type, plate format and instrument; the values here are starting points requiring local titration.
ECAR-derived parameters describe acidification under assay conditions, not glycolytic flux in the culture conditions the cells normally experience.
Scientific interpretation and experimental design
- • ECAR is acidification. The buffer chemistry is part of the measurement.
- • Reserve is a difference, not a store.
- • Titrate density. Copied values rarely transfer.
- • Titrate oligomycin. Incomplete blockade inflates capacity.
- • 2-DG has a second effect. Glycosylation inhibition within the window.
- • Three baseline cycles are a diagnostic.
Selected references for further reading
- • Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements. Journal of Biological Chemistry. 2017;292:7189–7207.
- • TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods in Enzymology. 2014;542:91–114.
- • Divakaruni AS, Jastroch M. A practical guide for the analysis, standardization, and interpretation of oxygen consumption measurements. Nature Metabolism. 2022;4:978–994.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »